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ABSTRACT 
 
Background: Despite appropriate chelation therapy with desferrioxamine, iron deposition in 
visceral organs causes tissue damage in thalassemia major patients. Excess iron can generate 
reactive oxygen species (ROS) that may lead to cell death and apoptosis. Therefore, antioxidants 
such as plant flavonoids can be an effective treatment to reduce ROS in thalassemia patients.  
Aims: In this study, we aimed to investigate the serum levels of apoptosis markers in β-
thalassemia major patients treated with silymarin and desferrioxamine. 
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Study Design: This study was a randomized, double-blind, placebo controlled 6-month clinical trial 
Place and Duration of Study: This clinical trial was carried out at Sayed-Al-Shohada clinic of 
thalassemia, Isfahan University of Medical Sciences, Iran, for 6-month between August 2009 and 
February 2010. 
Methodology: The patients were randomized into two groups: one group (A) received 
desferrioxamine and placebo and the other group (B) received a combination of desferrioxamine 
and silymarin. Serum levels of soluble apoptosis markers including soluble Fas (sCD95,sFas), 
sCD95 ligand (sCD95L,sFasL), sTNF receptor type 1 (sTNFR1), sTRAIL and cytochrome C, were 
measured before and after the trial in two groups of 40 thalassemia major patients using ELISA 
kits. Statistical analysis was performed using SPSS 15 version for windows program; results were 
expressed as mean ± standard deviation (SD) and significance set at P< 0.05. 
Results: There was no statistically significant difference between desferrioxamine group and 
combined therapy group in serum concentration of apoptosis markers, except for sTNFR1 level 
(which decreased from 0.16±0.12 to 0.11±0.10ng/ml) in the silymarin treatment group (P<0.05). 
Conclusion: Our observation of decreased circulating concentrations of sTNFR1 in silymarin-
treated patients may reflect anti-inflammatory activity of silymarin in β-thalassemia major. The 
finding that silymarin treatment had no effect on the level of soluble apoptosis marker could be an 
evidence for safety of silymarin treatment in thalassemia major patients. However, measuring the 
membrane levels of these markers is necessary to validate these results, as they are not 
expressed equally in different tissues. 
 
 
Keywords: Thalassemia; desferrioxamine; silymarin; sTNFR1; sCD95; sTRAIL; cytochrome C; 
sCD95L; Fas. 
 
1. INTRODUCTION 
 
Iron overload is the most common clinical 
complication in thalassemia patients. Despite 
appropriate chelation therapy (e.g. 
desferrioxamine), iron deposition in visceral 
organs causes tissue damage [1]. The exact 
mechanism of tissue damage and iron deposition 
in visceral organs is not clear; however, it seems 
that generation of Reactive Oxygen Species 
(ROS) through the Fenton reaction is one of the 
possible mechanisms [2]. Antioxidants such as 
plant flavonoid can be an effective treatment to 
reduce ROS in thalassemia patients. Silymarin is 
a non-toxic flavonoid, which is widely consumed 
as a dietary supplement for its strong antioxidant 
and hepatoprotective activities. In a recent 
clinical trial, thalassemia patients with severe iron 
overload were safely treated with a combination 
of silymarin and desferrioxamine. Silymarin was 
generally well tolerated with no detectable 
abnormalities in complete blood count, 
differential cell counts, liver or renal functions 
[3,4]. 
 
Apoptosis is initiated by death-inducing 
transmembrane receptors. These receptors 
include TNF receptors and a variety of immune 
cell receptors and their corresponding ligands [5]. 
Also, apart from membrane-bound, receptors are 
detectable in soluble forms, due to shedding from 
the cell surface. In this study, we investigated 
serum concentrations of soluble apoptosis 
markers which include: CD95 (sCD95, sFas), 
sCD95 ligand (sCD95L, sFasL), sTNF receptor 
type 1 (sTNFR1), sTRAIL and cytochrome C in 
β-thalassemia major patients following a 
combined therapy of silymarin and 
desferrioxamine. 
 
2. PATIENTS AND METHODS 
 
Homozygous β-thalassemia major patients were 
selected from referrals to Sayed-Al-Shohada 
clinic of thalassemia, Isfahan University of 
Medical Sciences. All patients were received 
regular transfusion by leucodepleted blood 
prophylactically matched for D, C, E, c, e, and K1 
blood group to maintain the hemoglobin level 
above 9.5 g/dL and treated by subcutaneous 
desferrioxamine. Patients were excluded from 
the trial if they had one of the following 
conditions: under 12 years of age, chronic renal 
or heart failure, iron chelation therapy with iron 
chelators other than desferrioxamine, hepatitis B 
or C infection, a history of a positive HIV test, 
pregnancy, and antioxidant or herbal medicine 
consumption. Oral and written informed consents 
were obtained from all patients. The protocol for 
this study was approved by the Ethics Committee 
of the Isfahan University of Medical Sciences, 
Isfahan, Iran (Ethical approval number: 187050). 
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This study was a randomized, double-blind, 
placebo controlled, 6-month clinical trial of 
silymarin add-on therapy in β-thalassemia major 
patients on regular iron chelation therapy by 
desferrioxamine. Patients were randomized into 
a treated group and a placebo group based on 
the date of their first visit after enrollment. The 
treated group received 140 mg Legalon®, 
Madaus Pharma orally, at least an hour before 
food, three times a day, 7 days a week with their 
routine desferrioxamine (Novartis Pharma AG, 
Basel, Switzerland) dose of 4–6 days per week. 
The placebo group received tablets, identical to 
Legalon®, that were specially prepared for this 
study. During the study period, no change was 
allowed in the dose of desferrioxamine. 
Compliance with Legalon was assessed by pill 
counts and diary cards that recorded the time 
and date of taking each pill. Patients received a 
new supply of capsules every month, and they 
returned all diary cards at the same time. 
 
Fasting blood samples were taken from patients 
before a scheduled transfusion. Samples were 
drawn from all subjects and allowed to clot at 
room temperature and separated following 
centrifugation at1000xg for 10 min. Serum was 
stored at−80°C until analyzed. Serum soluble 
apoptosis markers in both placebo and silymarin 
groups were measured using enzyme-linked 
immunosorbent assay (ELISA) kits, according to 
the manufacturer’s instructions (Bender Med 
Systems, Vienna, Austria). The sensitivity of the 
ELISA kits was 13.2 pg/ml for sFas, 0.7 ng/ml for 
sFasL, 0.05 ng/ml for sTNFR1, 0.05 ng/ml for 
cytochrome C, and 5 pg/ml for sTRAIL. 
 
2.1 Statistical Analysis 
 
Statistical analysis was performed using SPSS 
15 version for windows program. Statistical 
significance of the differential circulating levels of 
apoptotic markers in thalassemia patients was 
determined using t-test of two independent 
samples. The mean ± standard deviation (SD) 
was calculated for all data and significance was 
set at P value<0.05. 
 
3. RESULTS 
 
Clinical characteristics of β-thalassemia major 
patients are summarized in Table 1. A total of 80 
thalassemia patients in two groups were 
successfully recruited into the study. In the 
placebo group, 40 patients continued receiving 
desferrioxamine, and in the silymarin group, 40 
patients received a combined regimen of 
desferrioxamine and Legalon. There were no 
statistically significant differences in the mean 
levels of sFas, sFasL, TNFR1 and cytochrome C 
between placebo group and silymarin group at 
the baseline and after treatment. Moreover, the 
concentration of these serum soluble markers 
was slightly higher or below the kits detection 
limits in both groups. The sTRAIL was not 
detectable in two groups. Results are expressed 
as the mean of soluble apoptosis markers ± SD 
in Table 2. 
 
Table 1. Clinical and biological features of 
patients with β-thalassemia major 
 
Features Values 
Age (year)                                                                                   
Hemoglobin (g/dl)                                                                       
Body mass index (kg/m2)                                                  
Desferrioxamine dosage (mg/kg)                                               
Desferrioxamine 
treatment(nights/week)                                  
Transfusion interval (day)                                                          
Transfusion volume (ml)a 
Splenectomy (%)                                                            
21.8±5.4 
9.5±0.9
20.26±2.6 
40–50
5±1 
16.8±3.2 
535±123
45.71 
a
 Transfusion volume is the volume of blood that is transfused 
to patients in each transfusion referral 
 
Table 2 shows in significant differences in serum 
concentration of apoptosis markers (P>0.05) 
except for sTNFR1 where a significant decrease 
was observed (P<0.05). 
 
4. DISCUSSION 
 
In the present study, we found that the serum 
levels of sFas, sFasL, sTRAIL and cytochrome C 
showed no significant difference between 
silymarin and placebo groups; however, serum 
level of sTNFR1 was significantly reduced after 
silymarin treatment, while no change was 
observed in sTNFR1 levels in placebo treated 
patients. In various pathologic conditions 
including chronic inflammatory diseases and 
infections, the serum concentrations of TNFα 
and sTNFR increase, which their balance may 
appear to reflect the activation state of the 
TNFα/TNFR system. Soluble forms of TNFR are 
the only natural molecules known to interfere 
with TNF activity by competing for TNF binding 
with receptors on target cells. Elevated levels of 
serum TNFα was reported previously in β- 
thalassemia major patients, which was 
decreased significantly by silymarin treatment in 
this study. Therefore, our observation of 
decreased circulating concentrations of sTNFR1 
in silymarin-treated patients correlates with 
decreased TNFα levels, which may reflect anti-
inflammatory activity of silymarin in β-
thalassemia major patients. 
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Table 2. Mean ± SD serum concentrations of sFas, sFasL, TNFR1, and cytochrome C in 
thalassemia patients treated with placebo (group A) orsilymarin (group B) 
 
Apoptosis 
markers 
Placebo (Group A; n=40) Silymarin (Group B; n=40) 
Before After P-value Before After P-value 
sFas (pg/ml) 22.15±15.82 19.52±12.08 0.142 24.68±24.22 26.17±29.84 0.516 
sFasL (pg/ml) 117.41±95.34 114.87±62.44 0.896 172.18±155.13 126.89±113.56 0.150 
sTNFR1 (ng/ml) 0.12±0.09 0.11±0.11 0.747 0.16±0.12 0.11±0.10 0.029* 
Cytochrom C 
(ng/ml) 
0.15±0.02 0.15±0.02 0.595 0.17± 0.16 0.21±0.29 0.204 
P-value is significant at P<0.05, *= significant 
 
Although we do not yet completely understand 
the underlying mechanism of apoptosis in 
thalassemia patients, the production of ROS 
through Fenton reaction and iron-mediated 
oxidationas well as death receptor mediated 
pathways such as Fas-FasL ligand interactions 
could be possible explanations for inducing 
apoptosis in thalassemia patients [1,6]. Previous 
studies revealed that murine sFasL is a non-
apoptotic ligand and can act as an antagonist of 
membrane- bound FasL (mFasL) activity [7]. 
Considering the high percentage of CD3+Fas+ T 
lymphocytes in thalassemia major patients 
previously reported by Gharagozloo et al. [8], the 
low serum levels of sFas and sFasL markers 
may correspond to high levels of Fas+ T 
lymphocytes  in β-thalassemia major patients. 
 
5. CONCLUSION 
 
This study provides further evidence of anti-
inflammatory effect of silymarin treatment in β-
thalassemia major patients. The finding that 
silymarin had no effect on the level of soluble 
apoptosis marker could be an evidence that 
supports silymarin as a safe treatment for β-
thalassemia major patients. Since apoptosis 
markers are not expressed equally in different 
tissues and affected by several factors, 
evaluation of membrane apoptosis markers is 
necessary to verify the result of current study on 
serum soluble markers. In this study we 
compared the levels of apoptotic factors in their 
soluble forms, further trials assessing the 
membrane levels of such markers and related 
parameters can help us to have a better 
understanding of the underlying mechanism of 
apoptosis and tissue damage in thalassemia 
patients and how silymarin can affect this 
phenomenon. 
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